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Aims. Left ventricular (LV) mechanics have been
extensively investigated in heart failure with pre-
served ejection fraction (HFpEF) overshadowing for
a long time the potential role of left atrium (LA) in
that setting. Soluble suppression of tumorigenic-
ity-2 receptor (ST2) is a novel biomarker of pro-
fibrotic burden in HF. We hypothesized that due to
the thinner LA wall, the fibrotic myocardial
changes in HFpEF as indicated by elevated ST2
levels might more readily be reflected by impair-
ments in the LA rather than the LV performance.
Methods and Results. In 86 patients with HFpEF,
enrolled in the Karolinska Rennes (KaRen)
biomarker prospective substudy, global LA strain
(GL-LS) along with other echocardiographic as well
as haemodynamic parameters and ST2 levels were
measured.ST2 levels were inversely associated
with LA-GS (r = 0.30, P = 0.009), but not with
LA size, LV geometry, systolic or diastolic LV
function (P > 0.05 for all). Furthermore, symptom
severity correlated with ST2 and LA-GS, but not
with LV structural or functional indices. Finally,
during a median 18-month follow-up, LA-GS
independently predicted the composite endpoint
of HF hospitalization and all-cause mortality,
even after adjustment for potential clinical and
cardiac mechanical confounders, including LV
global longitudinal strain and filling pressures
(odds ratio: 4.15; confidence interval: 1.2–14,
P = 0.023).
Conclusions. Reduced LA-GS but not LV functional
systolic and diastolic parameters were associated
with the pro-fibrotic ST2 marker, HF symptoms
and outcome in HFpEF.
Keywords: ST2, heart failure, preserved ejection frac-
tion, left atrial strain, prognosis.
Introduction
Heart failure with preserved ejection fraction
(HFpEF) accounts for up to half of patients with
heart failure (HF) [1, 2], with a prognosis compa-
rable to that of HF with reduced ejection fraction
(EF) [1] and an increasing prevalence.
For a long time, investigations aiming to uncover
the pathophysiology underlying HFpEF have
focused on left ventricular (LV) mechanics;
however, no pathognomonic LV functional or
structural alterations have been identified. While
LV hypertrophy is common in HFpEF, nearly half of
the HFpEF patients show no signs of hypertrophy
[2]. Similarly, although increased LV stiffness is
typical in this patient population [3, 4], it may also
occur in subjects without clinical signs and symp-
toms of HF [5]. Furthermore, whereas LV diastolic
dysfunction is considered as a hallmark of HFpEF,
abnormal diastolic LV performance is an almost
universal finding in elderly patients without HFpEF
[5], which underscores the significance of other
mechanisms in the pathophysiology of HFpEF.ClinicalTrials.gov. NCT00774709
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Recently, a subtle shift in the focus of interest in
the HFpEF field has occurred with an increasing
number of studies investigating the role of the left
atrium (LA) rather than that of the LV in the HFpEF
[6–9]. Elevated filling pressures and subsequent LA
dilation are a characteristic finding in HFpEF. The
degree LA enlargement reflects disease chronicity
[10] and is prognostic in HFpEF [9]. Importantly,
apart from the structural remodelling, increased
LA stiffness has also been demonstrated in HFpEF,
which further aggravates the elevated LA pres-
sures, particularly during exertion.
Increasing evidence supports the concept that
HFpEF ultimately develops on the basis of a pro-
inflammatory state triggered by comorbidities [11].
The soluble suppression of tumorigenicity-2 recep-
tor (ST2) is an established biomarker of inflamma-
tion and fibrosis with an emerging role in the
diagnosis and prognostication of HF. In the context
of HF, ST2 expression is thought to be triggered by
myocardial stretch and consequent fibrosis [12]. In
patients with reduced EF, ST2 has superior prog-
nostic power compared to conventional biomarkers
such as N-terminal pro-brain natriuretic peptide
(NT-proBNP) [13]. Patients with HFpEF also
demonstrate elevated ST2 levels. Interestingly how-
ever, in this condition no significant correlation
between ST2 levels and LV structure or function
has been found [14].
As HFpEF is postulated to develop as a result of a
systemic inflammatory reaction, we hypothesized
that the LA, given its much thinner wall, is likely to
be more susceptible to fibrotic changes as com-
pared to the LV. Thus, early signs of the disease, as
indicated by elevated ST2 levels, might more
promptly manifest in altered LA mechanics, rather
than in impaired LV performance. Accordingly,
employing information from the biomarker Karolin-
ska Rennes (KaRen) prospective, multicentre sub-
study, we tested the hypothesis that in HFpEF (1)
plasma ST2 levels correlate with LA function; and
(2) impaired LA function is associated with worse
outcomes.
Materials and methods
Study population
The study included 86 HFpEF patients enrolled in
the prespecified KaRen Biomarker Study which
comprised a substudy of the Karolinska Rennes
(KaRen) prospective, observational, multicentre
study [15]. Patients admitted for acute HF
symptoms, NT-proBNP >300 ng L1 and LVEF
≥45% were enrolled between May 2007 and Decem-
ber 2011. Four to 8 weeks after enrolment, when
patients were in a stable condition, blood samples
were taken and clinical investigations, including
echocardiography, were performed. The patients
were followed until September 2012 when vital
status was assessed by telephone contact or by the
Swedish National Patient and Population Registers
and then centrally adjudicated. All HF hospitaliza-
tions were adjudicated and defined according to
clinical judgement by the local specialist investi-
gator and additionally centrally validated to con-
firm the presence of HF at hospitalization. The
primary outcome was the composite of time to
death from any cause or first hospitalization for HF
(Figure S1).
Biomarker assays
Fasting blood samples were taken from subjects in
a stable condition and euvolaemic state, collected
in chilled EDTA tubes, immediately centrifuged at
4 °C and stored in aliquots at 70 °C until anal-
ysis. NT-proBNP was analysed by proBNPII (Roche
Diagnostics, Bromma, Sweden). Plasma ST2 levels
were measured by the Presage ST2 Assay (Critical
Diagnostics, San Diego, California). Estimated
glomerular filtration rate (eGFR) was calculated
according to the MDRD study equation:
GFR ½mL=min=1:73m2 ¼ 175 ½creatinine1:154
 ½Age0:203  ½0:742 if female;
Creatinine in mg/dL, age in years:
Echocardiographic data
All subjects underwent transthoracic echocardio-
graphy using a Vivid-7 system (GE Ultrasound,
Horten, Norway) equipped with a 2.5-MHz matrix
array transducer. Images were analysed offline
(EchoPAC PC, version 2.0 GE Ultrasound, Wauke-
sha, Wisconsin) by a single echocardiographer,
blinded to the patients’ clinical data. Stroke
volume index (SVi) was measured by Doppler
method. For LA volumetric analysis, the method
of disc method was used. Myocardial deformation
was analysed by two-dimensional speckle track-
ing, using dedicated software designed for the LV
and LA, respectively (TomTec Imaging Systems,
Unterschleissheim, Germany). LV global longitu-
dinal strain (LV-GLS) was calculated as the aver-
age of longitudinal strain measured in 12
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segments obtained from the apical four- and two-
chamber views. LA global strain (LA-GS) was
measured in the apical two-chamber view, accord-
ing to the manufacturer’s recommendations. The
LA endocardial border was traced so that the LA
appendage and pulmonary veins were excluded.
LA reservoir function was estimated by peak LA-
GS during ventricular systole. All measurements
were averaged over 3 cardiac cycles. At the time of
echocardiographic examination, 21 patients were
in atrial fibrillation (AF). In these cases, measure-
ments were averaged over 5 cycles. In case of
significant foreshortening of the cavity or poor
tracking quality, the measurements were consid-
ered unreliable and excluded from the analysis
(n = 7).
Intra-observer variability for LA-GS measurements
was assessed in 10 randomly selected patients.
The coefficient of variation was 8%, and the intr-
aclass correlation coefficient was 0.94 (95%
CI = 0.631–0.991).
Measurements of the atrioventricular coupling and vascular function
Effective arterial elastance (Ea) constitutes a
‘lumped index’ of LV afterload in the time domain
and was calculated as Ea = LVESP/SV, where
LVESP is the LV end-systolic pressure. LVESP
values were estimated as derived from the equa-
tion: LVESP = 0.9 9 SBP, where SBP is the systolic
systemic blood pressure [16]. LV end-systolic elas-
tance (Ees) was calculated using the single-beat
approach developed by Chen et al [17]. Total
arterial compliance was estimated by the SV-to-
pulse pressure ratio [18] and systemic vascular
resistance index (SVRi) as: mean arterial pressure/
cardiac index 9 80.
Assessment of LV relaxation rate and filling pressures
The mean value of the lateral and septal mitral
annular early diastolic velocity (e0) was deter-
mined by spectral tissue Doppler imaging using
standard methods. The e0 velocity is relatively
preload independent and inversely related to the
time constant of isovolumic relaxation (tau),
which was derived from the previously validated
formula:
tau = (14.70–100 9 e0)/0.15 [19]. Early transmi-
tral flow velocity (E) was measured by pulsed-wave
Doppler. LV end-diastolic pressure (LVEDP) was
estimatedas follows:LVEDP = 11.96 +0.596 9 E/e0,
as previously determined fromDoppler and invasive
EDP measurements [19].
Determination of LV diastolic stiffness
The validated single-beat approach [20] was used
to characterize the LVEDP–end-diastolic volume
(EDV) relationship (EDPVR) based on the equation:
EDP = a 9 EDVb; where a is a curve-fitting con-
stant and b is the diastolic stiffness constant
describing the steepness of the EDPVR curve.
Measured EDP and EDV were used to derive a
and b in each subject. Additionally, LV end-
diastolic stiffness was assessed by the ratio
between EDP and EDV.
Ethics
The study conformed to the Declaration of Helsinki
had ethics approval by local ethics committees,
and all participants provided written informed
consent.
Statistics
IBM SPSS statistics version 23.0 (IBM Corp.,
Armonk, NY, USA) was used. Normality was tested
using the Kolmogorov–Smirnov test. Continuous
variables were expressed as mean  SD or median
and interquartile range (IQR) whereas categorical
variables as absolute values and percentage.
Comparisons between groups were performed with
Mann–Whitney rank-sum test. Correlations were
tested by the Pearson’s two-tailed test. All tests
were performed at 95% confidence intervals. All P-
values were two-sided, and statistical significance
was, except for the Bonferroni-adjusted correla-
tions, set at 0.05. HFpEF patients were categorized
according to quartiles of LA-GS, and trend tests
were applied across the groups to investigate the
association between LA-GS and demographic char-
acteristics and echocardiographic measures of
cardiac structure and function.
The association of LA-GS with the combined out-
come of death and/or hospitalization was tested
with univariate and multivariable Cox proportional
hazards models and Kaplan and Meier nonparamet-
ric test and compared using a log-rank test, using a
time-to-event analysis. Adjustment for demographic
and clinical covariates (age, history of AF, logST2,
eGFR, LV-GLS, LAVi, E/e0 and Ea) was performed.
The proportional hazards assumption was tested for
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all analyses. No violation of the proportional haz-
ards assumption by LA-GS was found.
Because of the biomarker levels not being normally
distributed, all biomarker data were natural-loga-
rithmically (log)-transformed.
Analysis of inter- and intra-observer variability was
performed for LA-GS in 10 randomly selected
patients by two observers. Methodological error
(Err) in a single measurement estimated from
double measurements was calculated according to
formula: Err = (SDdiff 9 100%)/(total mean 9 √2),
where SDdiff is the SD of the difference between
the measurements [21].
Results
Demographic characteristics of the patient popu-
lation are provided in Table 1. Median EF for the
whole cohort was 63% (Q1:57%, Q3:68%). At the
time of enrolment, all patients were highly symp-
tomatic (88% in New York Heart Association func-
tional class (NYHA) III-IV, 12% in NYHA II status);
however, when the echocardiographic examination
and biochemical analyses were performed (in
stable state 4–8 weeks after enrolment), the symp-
toms were significantly alleviated (17% in NYHA III,
59% in NYHA II and 23% in NYHA I; 69% on
diuretics).
Similar to prior studies in HFpEF, there was a
slight over-representation of women (51% vs. 49%)
and nearly half (41%) of the patients demonstrated
severe obesity. Fifty-two patients (60%) had previ-
ously been diagnosed with AF, of whom 21 were in
AF at the time of the echocardiographic examina-
tion.
ST2 levels and cardiac mechanics
The median ST2 concentration in our cohort was
32 ng mL1 [Q1:24–Q3:48 ng mL1]. Serum ST2
levels inversely correlated with LA-GS (r = 0.30,
P = 0.009, Fig. 1a). However, no association was
found between ST2 and the degree of LA enlarge-
ment (LA volume index, LAVi) or with indices of LV
geometrical remodelling (LV mass index (LVMi), LV
systolic and diastolic volumes), LV systolic func-
tional parameters (LVEF, LV-GLS, Ees), measures
of the LV relaxation and end-diastolic function
(tau, b, EDP/EDV, E/e0) or indices of the AV-
coupling and the systemic vascular function
(Ea/Ees, arterial compliance, SVRi). Importantly,
Table 1 Demographic data
General
Age years 72  10
Gender male/female 42/44 (49/51)
Medical history
Atrial fibrillation/flutter 52 (60)
Hypertension 68 (79)
Diabetes mellitus 28 (33)
COPD 17 (20)
Cancer 15 (17)
Coronary disease 13 (15)
NYHA I 19 (22)
NYHA II 46 (53)
NYHA III 19 (22)
NYHA IV 0
Clinical measurements
BMI kg m2 30  6
Obesity (BMI ≥ 30) 34 (41)
SBP (mmHg) 142  21
DBP (mmHg) 79  9
HR (beats/min) 70  15
Treatment
ARB or ACE-I 65 (76)
Statin 37 (43)
Digoxin 10 (12)
Loop diuretic 59 (69)
Beta-blocker 67 (80)
Calcium channel blocker 26 (30)
Laboratory findings
NT-proBNP (ng∗L1) 1000 (Q1:465;Q3:2335)
ST2 (ng∗mL1) 32 (Q1:24;Q3:48)
eGFR (mL∗min1/
1.73 m2)
70 (Q1:54;Q3:85)
Haemoglobin (g∗L1) 13.1 (Q1:12.2;Q3:14.2)
White blood cell
count (109/L)
8.0 (Q1:7.1;Q3:9.9)
COPD, chronic obstructive pulmonary disease; NYHA,
New York Heart Association functional class; BMI, body
mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HR, heart rate; ARB, angiotensin recep-
tor blocker; ACE-I, ACE inhibitor; NT-proBNP, N-term-
inal pro-brain natriuretic peptide; ST2, soluble
suppression of tumorigenicity-2 receptor; eGFR, esti-
mated glomerular filtration rate. Data are provided as
absolute numbers followed by percentages in brackets;
or median values followed by 1st (Q1) and 3rd (Q3)
quartiles in brackets
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an inverse association of ST2 with RV function, as
assessed by tricuspid annular plane systolic excur-
sion (TAPSE), was demonstrated (r = 0.28,
P = 0.01), whereas no correlation between ST2
and renal functional indices (s-Creatinine, eGFR)
or CRP was observed.
Determinants of LA strain
The LA-GS did not show significant association
with the LVMi or LV volumes. Although it was
significantly related to the SV (r = 0.23, P < 0.05),
no correlation with other indices of LV systolic
performance (LVEF, LV-GLS; Ees) was evident.
Similarly, LA-GS was not associated with either
the LV end-diastolic function as assessed by EDP/
EDV ratio, or the b value representing the slope of
the EDPVR or the preload as estimated by E/e0.
On the other hand, LA-GS was inversely related
with LV afterload as described by Ea (r = 0.28,
P = 0.01). Importantly, no significant relationship
between LA-GS and LAVi was found. Similar to
ST2, LA-GS was also significantly associated with
TAPSE (r = 0.41, P < 0.001). In a multiple regres-
sion analysis, including logST2, age, eGFR,
LV-GLS, LAVi, E/e0 and Ea as potential predic-
tors, only logST2 and eGFR were identified as inde-
pendent predictors of the LA-GS (LA-GS = 39.7–
5.4 ∗ logST2-0.113 9 eGFR; P = 0.003). However,
when the occurrence of AF was added in
the analysis, eGFR and AF only remained as
predictors of LA-GS (LA-GS = 29.3–7.8 ∗ AF-
0.092 9 eGFR; P = 0.001). When we restricted
the above analysis to patients in sinus rhythm,
similar to the entire population, only eGFR and
logST2 acted as independent predictors of LA-GS
(LA-GS = 2.636–0.28 ∗ logST2-0.115 9 eGFR;
P < 0.001).
Association between HF symptoms and indices of LA and LV function
In order to investigate the relationship between
the functional status and cardiac performance,
we dichotomized our study cohort into asymp-
tomatic patients (NYHA I, n = 19) and those with
moderate to severe symptoms (NYHA II-III,
n = 65). LA-GS and ST2 were the only markers
demonstrating significant difference between the
two groups (LA-GS: 18.7  10.7 vs. 11.7  10.8%,
P = 0.01; ST2: 30.2  14.1 vs. 42.8  29.0
ng mL1, P = 0.04, asymptomatic vs. symptomatic
patients) (Fig. 1). On the other hand, neither the
systolic (LV-GLS, SVi) nor the diastolic LV metrics
(b, tau, EDP/EDV, E/e0) or AV-coupling and the
vascular function indices (Ea, SVRi) differ signifi-
cantly between the two groups (Fig. 2). Additionally,
there was no difference in NYHA class between
patients in sinus and those in AF during the
examination (P = 0.62).
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Fig. 1 Left atrial strain and ST2 levels. (a) correlation between plasma soluble suppression of tumorigenicity-2 receptor
(ST2) levels and left atrial strain (LA-GS) (r = 0.3, P = 0.009). (b) Comparison of ST2 levels between patients with LA-
GS < 20% and LA-GS ≥ 20%.
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LA strain and outcome
To investigate whether increased LA stiffness as
assessed by LA-GS had a direct influence on
patient prognosis, we dichotomized our patient
cohort based on the LA-GS, using the third
interquartile (LA-GS: 20%) as a cut-off value.
As shown in Table 2, patients with LA-GS < 20%
displayed significantly lower SVi, LV-GLS and RV
function along with higher Ea. Importantly, E/e
0
values were similar in the two groups. ST2 and NT-
proBNP levels were higher in patients with more
reduced LA-GS, whereas eGFR did not significantly
differ between the two groups.
Over a median follow-up of 572 days (IQR: 467–
1369), 32 primary outcome events occurred (five
deaths, 27 first HF hospitalizations). No patients
were lost to follow-up. LA-GS < 20% was associ-
ated with an increased risk of the primary com-
posite endpoint (P = 0.02) in unadjusted analysis
[odds ratio (OR) 3.23; confidence interval (CI) 1.1–
9.3, P = 0.029]; Fig. 3a. After adjustment for age,
eGFR, LV-GLS and tau, LA-GS remained an inde-
pendent predictor of the outcome [OR: 4.15; CI:
1.2–14, P = 0.023]; Fig. 3b.
As AF impacts on LA functional parameters, we
proceed by further adjustment employing AF as
covariate in the aforementioned regression model.
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Fig. 2 Association between heart failure symptoms, echocardiographic parameters and ST2 levels. Comparison of left
atrial strain (LA-GS) (a), soluble suppression of tumorigenicity-2 receptor (ST2) levels (b), left atrial volume index (LAVi) (c)
and left ventricular global longitudinal strain (LV-GLS) (d) between patient groups with (NYHA II-III) or without (NYHA I) heart
failure symptoms. NYHA, New York Heart Failure Functional Classification.
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LA-GS retained its significant predictive ability
[OR: 4.56; CI: 1.3–15.7, P = 0.016] although sig-
nificant but weaker predictive capacity was even
demonstrated for LV-GLS [P = 0.042]; in contrast,
neither the indices of AV-coupling (Ea, Ees, Ea/Ees)
nor the E/e0 demonstrated any predictive ability for
death or hospitalization. In addition, selective
analysis of the patients in sinus rhythm also
showed that, after adjustment for age, eGFR, tau
and LV-GLS, LA-GS remained an independent
predictor of outcome in this population [OR: 4.24;
CI: 1.2–14.9, P = 0.019].
Discussion and conclusion
In the present prospective study, we demonstrate
that in HFpEF: (i) pro-fibrotic changes as indicated
by the ST2 biomarker are associated with
Table 2 Cardiac and vascular geometric and functional measures in the two groups stratified according to LA-GS.
Entire cohort LA-GS < 20% LA-GS ≥ 20% P-value
BMI 29.5  6.0 (57) 30.4  6 (20) NS
Age 72.8  8 (59) 71.9  10 (20) NS
SBP (mmHg) 141  20 (59) 148  22 (20) NS
DBP (mmHg) 78  8 (59) 80  11 (20) NS
LV dimensions
LV EDVi (mL∗m2) 56.6  14 (82) 57.2  15.1 (58) 55.7  12 (20) NS
LV ESVi (mL∗m2) 23.9  11 (82) 25.3  11.2 (58) 20  7 (20) NS
LVMi (g∗m2) 120  31 (82) 119.6  34 (58) 118  20 (20) NS
LV systolic function
LVEF (%) 62.5  7 (82) 61.6  7.6 (58) 65.2  5 (20) NS
LV-GLS (%) 15.3  3.6 (80) 14.9  3.7 (58) 16.9  3 (18) 0.03
SVi (mL∗m2) 37.4  11 (81) 35.6  10.8 (58) 43.4  10 (19) 0.012
Ees (mmHg∗mL
1) 2.2  0.9 (81) 2.2  0.9 (58) 2.1  0.8 (19) NS
LV diastolic function
E/A ratio 1.8  1.4 (60) 2.2  1.6 (40) 1.1  0.3 (20) 0.008
e0 mean 7.9  2.2 (83) 8.2  2.4 (58) 7.0  1.5 (20) NS
E/e0 mean 12.6  6 (83) 12.7  6.1 (57) 12.7  5 (20) NS
LVEDP (mmHg) NI 19.5  3.4 (82) 19.5  3.6 (57) 19.5  2.7 (20) NS
Tau (ms) NI 45  15 (81) 43.4  15.9 (57) 50.9  10.2 (20) NS
b 6.0  0.4 (81) 5.98  0.46 (57) 6.03  0.4 (20) NS
EDP/EDV (mmHg∗mL1) 0.19  0.06 (81) 0.19  0.1 (58) 0.18  0.04 (20) NS
Vascular function
Ea 1.96  0.8 (81) 2.1  0.9 (58) 1.6  0.3 (19) 0.035
Ea/Ees 1.0  0.42 (81) 1.1  0.4 (58) 0.8  0.3 (19) NS
SVRi (mmHg∗L1∗m2) 47.4  15 (83) 48  16 (58) 46.7  13.2 (20) NS
Arterial compliance
(mL∗mmHg1)
0.72  0.22 (81) 0.69  0.2 (58) 0.83  0.2 (19) NS
LA function
LA ESVi (mL∗m2) 44.4  16 (79) 44.4  17.1 (59) 44.2  14 (20) NS
LA-GS (%) 13.3  11 (79) 8.1  6.3 (59) 28.7  7 (20) <0.0001
LA EF (%) 28.6  18.4 (79) 21.7  15.2 (59) 49.1  10.1 (20) <0.001
RV function
TAPSE (mm) 16.5  4 (83) 15.7  4.1 (58) 19.1  4 (20) 0.003
ST2 reflects LA dysfunction in HFpEF / A. I. Nagy et al.
386 ª 2018 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine, 2018, 283; 380–391
mechanical alterations of the LA but not the LV;
and (ii) the LA strain comprised an independent
predictor of death or hospitalization independently
of the degree of LV remodelling or dysfunction.
The LA reservoir function is influenced by both LV
systolic function and the intrinsic LA compliance
and plays an important role in disease progression
in various pathologies including AF, acute myocar-
dial ischaemia and HF. LA strain is an emerging
noninvasive method for the quantification of LA
reservoir function [6].
Left atrium strain has been shown to reflect the
extent of LA fibrosis in various pathological states.
Kuppahally et al. [22] assessed the degree of LA
wall fibrosis by delayed-enhancement MRI in AF
patients and found that LA strain inversely asso-
ciated with the degree of LA fibrosis. In another
report, in patients undergoing mitral valve surgery,
preoperatively measured LA strain was the stron-
gest independent predictor of the degree of
histopathologically quantified LA wall fibrosis [23].
In our study, ST2, an established pro-fibrotic
marker, significantly associated with LA-GS. Con-
versely, measures of the systolic, early diastolic
and late diastolic LV function or those of the AV-
coupling and vascular function were not related to
ST2 levels. In agreement with our results, previous
studies in HFpEF failed to demonstrate any rela-
tionship between ST2 levels and LV echocardio-
graphic parameters [14, 24]. Even though ST2 has
repeatedly been shown to be a reliable marker of
disease severity in HFpEF, the aforementioned
observation has led to the misconception that
elevated ST2 might barely indicate systemic
inflammation, rather than reflect direct cardiac
alterations [14, 25]. No studies, however, have
specifically investigated the association between
LA function and ST2 levels in HFpEF.
The LV contraction towards the apex is expected to
act as a major determinant of the LA deformation
during systole [26]. In our cohort, however, no
association between the LV longitudinal deforma-
tion and LA-GS was found. This might be explained
by disparate responses of the LA and the LV to
inflammation, as myocardial remodelling at the
atrial level has been shown to involve differential
pathophysiologic pathways from the LV. In a
tachycardia-induced HF model, considerably dif-
ferent cellular responses were observed in these
two chambers, with more pronounced inflamma-
tory and pro-fibrotic reaction detected in the LA as
compared to the LV wall [27]. In another study,
angiotensin II infusion resulted in progressive LA
fibrosis that was independent of LV wall stress but
directly related to circulating hormone levels [28].
Conceivably, due to its thinner wall, the LA might
be more susceptible to myocardial fibrosis and
exhibit more apparent mechanical changes as
compared to LV. Our results advocate that LA-GS
comprises a surrogate marker of LA mechanical
changes partly ascribed to a pro-fibrotic reaction
and imply that LA structural and functional
Table 2 (Continued )
Entire cohort LA-GS < 20% LA-GS ≥ 20% P-value
Biochemical
NT-proBNP (ng∗L1) 1400 (Q1:556; Q3:2633) 495 (Q1:430; Q3:822) 0.003
ST2 (ng∗mL1) 35.0 (Q1:25; Q3:55) 26.7 (Q1:19; Q3:33) 0.003
eGFR (mL∗min1/1.73 m2) 70 (Q1:56; Q3:86) 59.5 (Q1:45; Q3:80) NS
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LV, left ventricle; EDVi, end-diastolic
volume index; ESVi, end-systolic volume index; LVMi, LV mass index; EF, ejection fraction; LV-GLS, LV global
longitudinal strain; SVi, stroke volume index; Ees, LV end-systolic elastance; E/A, ratio between the early diastolic inflow
velocity (E) to the inflow velocity due to atrial contraction (A); e0 mean, mean value of early myocardial velocity in LV basal
septal and lateral wall; E/e0, ratio between the E and the e0; EDP, end-diastolic pressure; NI, noninvasive; tau, time
constant of LV isovolumic relaxation; b, diastolic stiffness constant describing the steepness of the EDPVR curve; EDP/
EDV, end-diastolic pressure-to-end-diastolic volume ratio; Ea, effective arterial elastance; SVRi, systemic vascular
resistance index; LA, left atrium; LA ESVi, left atrial end-systolic volume; LA-GS, left atrial global longitudinal strain; LA
EF, left atrial ejection fraction; TAPSE, tricuspid annular plane systolic excursion; NT-proBNP, N-terminal pro-brain
natriuretic peptide; ST2, soluble suppression of tumorigenicity-2 receptor; eGFR, estimated glomerular filtration rate; NS,
nonsignificant (P ≥ 0.05). Data are provided as mean  SD followed by patient number in brackets; or median values
followed by 1st and 3rd quartiles in brackets.
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abnormalities might develop on the ground of
intrinsic LA alterations, independently of LV dys-
function.
Normally, the distensible LA accommodates blood
from the pulmonary veins without a considerable
rise in the LA pressure (LAP). In cases of reduced
LA compliance, as in LA fibrosis, the LA pressure–
volume curve is shifted upwards resulting in dis-
proportional rise of LAP for the same volume
entering the chamber. Chronically elevated LAP
leads to LA enlargement. Based on physical prin-
ciples, increased LA volume would mitigate the
elevated wall stress and accordingly the LAP.
Paradoxically however, the degree of LA remod-
elling has been shown to be positively related to the
severity of pulmonary hypertension [29]. This
observation can be physiologically explained by
concomitantly occurring LA wall fibrosis, which
counteracts the alleviating effect of LA volume
increase. Of note, in this study, LAVi was not
associated with either ST2 levels or the LA-GS.
Similar findings were also reported by others,
suggesting that the degree of LA fibrosis is not
solely or even primarily determined by the degree of
LA enlargement [6, 10], which supports our
hypothesis that LA fibrosis, as reflected by elevated
ST2, might be a result of an inflammatory process
rather than haemodynamic overload. In our study,
LA enlargement was not associated with the
patients’ functional class either, whereas a signif-
icant relationship between LA-GS and symptom
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Fig. 3 Left atrial strain and patient outcome. (a) Kaplan–Meier analysis of patients stratified by left atrial strain (LA-GS).
Group I, LA-GS < 20%; Group II, LA-GS ≥ 20%. (b) Hazard ratio for death or heart failure (HF) hospitalization for patients
with LA-GS < 20% compared to LA-GS ≥ 20%. eGFR, estimated glomerular filtration rate; LV-GLS, left ventricular global
longitudinal strain; tau, time constant of LV isovolumic relaxation; CI, confidence interval.
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severity was observed. Similar association was also
found between ST2 levels and symptomatology,
further supporting the notion of the potential
impact of inflammatory activity on LA mechanics.
LV diastolic properties have been extensively stud-
ied in regard to their association with symptoms in
HFpEF. Employing measurements with conduc-
tance catheters, Liu et al. [4] demonstrated that
HFpEF patients display increased LV end-diastolic
stiffness and impaired relaxation as compared to
healthy controls. These findings were confirmed in
a larger scale study in which noninvasive estimates
of LV relaxation and stiffness were used [8]. In
another report, however, early relaxation and LV
end-diastolic stiffness were similar between HFpEF
patients and healthy subjects at rest [30] and
elevated EDP in HFpEF was not accompanied by
increased b values advocating for the influence of
extracardiac forces rather than passive LV stiffness
on the elevated filling pressures. In our study,
indices of LV relaxation and diastolic stiffness did
not correlate with ST2 levels. However, there was a
weak association between tau and LA-GS suggest-
ing that apart from fibrotic changes, mechanical
alterations in the LV function during the relaxation
phase may also influence the LA mechanics.
LA strain and prognosis
To date, few studies have attempted to assess the
predictive value of LA function regarding outcome
in HFpEF. Recently, Melenovsky et al. [7] demon-
strated that LA EF was an independent predictor of
mortality in HFpEF. In another study, Santos and
colleagues showed that reduced LA strain implied
an increased risk of HF hospitalization in HFpEF
patients; however, it did not remain prognostic
after adjustment for LV deformation and the E/e0
[31]. Accordingly, the authors conclude that the
predictive ability of LA strain is to be attributed
merely to its association with LV performance [31].
Importantly, our findings contrast this observation
as we show that LA-GS independently predicted
outcome even when adjusted for measurements of
LV longitudinal systolic deformation and diastolic
performance as well as for indices of atrioventric-
ular coupling. These disparities might be explained
by differences in patient profile. Our cohort con-
sisted of older patients, in whom the structural and
functional LA indices as well as the higher preva-
lence of AF indicated more advanced disease. Also,
in the present work, a dedicated software for LA
strain analysis was employed, presumably yielding
more representative measurements, as compared
to earlier studies that applied LV strain measuring
algorithm for LA strain analysis.
Importantly, in our study other well-established
indices such as those describing the AV-coupling
and the E/e0 did not demonstrate significant prog-
nostic value. The later noninvasive marker of LA
filling pressures has been shown to entail signifi-
cant predictive value in HFpEF. Our findings
indicate that LA strain, reflecting not merely the
haemodynamic filling state but, as previously dis-
cussed, also the degree of pro-fibrotic alterations,
constitutes a more robust marker of disease sever-
ity in this clinical condition.
AF is a common condition in HFpEF that impor-
tantly influences LA-GS measurements and thus
could be a concern for the reliability and utility of
LA-GS measurement in these patients. In order to
rule out the confounding effect of AF on LA-GS
measurement, we tested the association of ST2
with LA-GS confining our analysis to patients in
sinus rhythm. ST2 showed a significant correla-
tion with LA-GS in these patients also. Similarly,
the independent prognostic value of LA-GS for
outcome was maintained in this subgroup of
patients.
Limitations
LA strain is a more and more widely used nonin-
vasive metric of LA reservoir function; however,
the actual haemodynamic meaning of LA strain is
rather ambiguous. Although the LA deformation
during systole is expected to represent a surrogate
of LA compliance, LA strain is also influenced by
other components of the cardiac mechanics. A
more accurate assessment of the LA reservoir
function would require direct measurement of LA
stiffness by an invasive approach, preferably with
micromanometric catheters. On the other hand,
the obvious correlations found with both ST2
levels and patient outcome speak for the utility
of LA strain, as a readily obtainable metric
providing clinically important information. The
relatively limited size of our study, as well as the
fact, that of the 32 outcome events that occurred
during follow-up, 27 were heart failure hospital-
izations, warrants larger scale investigations to
confirm our results. At the same time, the prog-
nostic information evident even at this patient
number corroborates the clinical significance of
our findings.
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Conclusions
Our results indicate that ST2 is a sensitive marker
of LA dysfunction in HFpEF, elevation of which
may specifically reflect LA mechanical alterations,
independently of LV performance. Impaired LA
strain remained an independent predictor of HF
hospitalization and mortality, even after adjust-
ment for clinical variables and LV functional
indices.
Considering the fact that currently no effective
therapy for HFpEF is available, a reliable tool for
monitoring the evolution of this disease is of
major clinical significance for the timely recogni-
tion and thus prevention of patients at increased
risk, prior to the development of irreversible LA
remodelling.
Sources of Funding
This project was supported by the Janos Bolyai
Scholarship of the Hungarian Academy of
Sciences.
Conflict of Interest
None.
References
1 Owan TE, Hodge DO, Herges RM et al. Trends in prevalence
and outcome of heart failure with preserved ejection fraction.
N Engl J Med 2006; 355: 251–9.
2 Zile MR, Gottdiener JS, Hetzel SJ et al. Prevalence and
significance of alterations in cardiac structure and function
in patients with heart failure and a preserved ejection
fraction. Circulation 2011; 124: 2491–501.
3 Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure–
abnormalities in active relaxation and passive stiffness of the
left ventricle. N Engl J Med 2004; 350: 1953–9.
4 Liu CP, Ting CT, Lawrence W et al. Diminished contractile
response to increased heart rate in intact human left
ventricular hypertrophy. Systolic versus diastolic determi-
nants. Circulation 1993; 88: 1893–906.
5 Redfield MM, Jacobsen SJ, Burnett JC Jr et al. Burden of
systolic and diastolic ventricular dysfunction in the commu-
nity: appreciating the scope of the heart failure epidemic.
JAMA 2003; 289: 194–202.
6 Santos AB, Kraigher-Krainer E, Gupta DK et al. Impaired left
atrial function in heart failure with preserved ejection frac-
tion. Eur J Heart Fail 2014; 16: 1096–103.
7 Melenovsky V, Hwang SJ, Redfield MM et al. Left atrial
remodeling and function in advanced heart failure with
preserved or reduced ejection fraction. Circ Heart Fail 2015;
8: 295–303.
8 Lam CS, Roger VL, Rodeheffer RJ et al. Cardiac structure and
ventricular-vascular function in persons with heart failure
and preserved ejection fraction from Olmsted County, Min-
nesota. Circulation 2007; 115: 1982–90.
9 Rossi A, Gheorghiade M, Triposkiadis F et al. Left atrium in
heart failure with preserved ejection fraction: structure,
function, and significance. Circ Heart Fail 2014; 7: 1042–9.
10 Melenovsky V, Borlaug BA, Rosen B et al. Cardiovascular
features of heart failure with preserved ejection fraction
versus nonfailing hypertensive left ventricular hypertrophy
in the urban Baltimore community: the role of atrial remod-
eling/dysfunction. J Am Coll Cardiol 2007; 49: 198–207.
11 Paulus WJ, Tschope C. A novel paradigm for heart failure with
preserved ejection fraction: comorbidities drive myocardial
dysfunction and remodeling through coronary microvascular
endothelial inflammation. J Am Coll Cardiol 2013; 62: 263–
71.
12 de Boer RA, Daniels LB, Maisel AS, Januzzi JL Jr. State of the
Art: Newer biomarkers in heart failure. Eur J Heart Fail 2015;
17: 559–69.
13 Zhou H, Ni J, Yuan Y et al. Soluble ST2 may possess special
superiority as a risk predictor in heart failure patients. Int J
Cardiol 2015; 186: 146–7.
14 AbouEzzeddine OF, McKie PM, Dunlay SM et al. Suppression
of tumorigenicity 2 in heart failure with preserved ejection
fraction. J Am Heart Assoc 2017; 6: e004382.
15 Donal E, Lund LH, Linde C et al. Rationale and design of the
Karolinska-Rennes (KaRen) prospective study of dyssyn-
chrony in heart failure with preserved ejection fraction. Eur
J Heart Fail 2009; 11: 198–204.
16 Kelly RP, Ting CT, Yang TM et al. Effective arterial elastance
as index of arterial vascular load in humans. Circulation
1992; 86: 513–21.
17 Chen CH, Fetics B, Nevo E et al. Noninvasive single-beat
determination of left ventricular end-systolic elastance in
humans. J Am Coll Cardiol 2001; 38: 2028–34.
18 Chemla D, Hebert JL, Coirault C et al. Total arterial compli-
ance estimated by stroke volume-to-aortic pulse pressure
ratio in humans. Am J Physiol 1998; 274: H500–5.
19 Ommen SR, Nishimura RA, Appleton CP et al. Clinical utility
of Doppler echocardiography and tissue Doppler imaging in
the estimation of left ventricular filling pressures: A compar-
ative simultaneous Doppler-catheterization study. Circulation
2000; 102: 1788–94.
20 Klotz S, Hay I, Dickstein ML et al. Single-beat estimation of
end-diastolic pressure-volume relationship: a novel method
with potential for noninvasive application. Am J Physiol Heart
Circ Physiol 2006; 291: H403–12.
21 Dahlberg G. Statistical Methods for Medical and Biological
Students. London: G. Allen & Unwin Ltd. 1940.
22 Kuppahally SS, Akoum N, Burgon NS et al. Left atrial strain
and strain rate in patients with paroxysmal and persistent
atrial fibrillation: relationship to left atrial structural remod-
eling detected by delayed-enhancement MRI. Circ Cardiovasc
Imaging 2010; 3: 231–9.
23 Cameli M, Lisi M, Righini FM et al. Usefulness of atrial
deformation analysis to predict left atrial fibrosis and endo-
cardial thickness in patients undergoing mitral valve opera-
tions for severe mitral regurgitation secondary to mitral valve
prolapse. Am J Cardiol 2013; 111: 595–601.
24 Zile MR, Jhund PS, Baicu CF et al. Plasma biomarkers
reflecting profibrotic processes in heart failure with a
ST2 reflects LA dysfunction in HFpEF / A. I. Nagy et al.
390 ª 2018 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine, 2018, 283; 380–391
preserved ejection fraction: data from the prospective com-
parison of ARNI with ARB on management of heart failure
with preserved ejection fraction study. Circ Heart Fail 2016;
9: e002551.
25 Bartunek J, Delrue L, Van Durme F et al. Nonmyocardial
production of ST2 protein in human hypertrophy and failure
is related to diastolic load. J Am Coll Cardiol 2008; 52: 2166–
74.
26 Appleton CP, Kovacs SJ. The role of left atrial function in
diastolic heart failure. Circ Cardiovasc Imaging 2009; 2: 6–9.
27 Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial
versus ventricular remodeling in dogs with ventricular tachy-
pacing-induced congestive heart failure. Cardiovasc Res
2004; 63: 236–44.
28 Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great
vessels in response to angiotensin II or aldosterone infusion.
Cardiovasc Res 1997; 35: 138–47.
29 Le Tourneau T, Richardson M, Juthier F et al. Echocardiog-
raphy predictors and prognostic value of pulmonary artery
systolic pressure in chronic organic mitral regurgitation.
Heart 2010; 96: 1311–7.
30 Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular
systolic and arterial stiffening in patients with heart failure
and preserved ejection fraction: implications for systolic and
diastolic reserve limitations. Circulation 2003; 107: 714–20.
31 Santos AB, Roca GQ, Claggett B et al. Prognostic relevance of
left atrial dysfunction in heart failure with preserved ejection
fraction. Circ Heart Fail 2016; 9: e002763.
Correspondence: Aniko Ilona Nagy, Semmelweis University, Heart
and Vascular Center, 68. Varosmajor u., 1122 Budapest,
Hungary.
(phone: +36-20-8259738; e-mail: anychophora@gmail.com)
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. Diagram illustrating the temporal
sequence of study events.
ST2 reflects LA dysfunction in HFpEF / A. I. Nagy et al.
ª 2018 The Association for the Publication of the Journal of Internal Medicine 391
Journal of Internal Medicine, 2018, 283; 380–391
